FCGR3A and neoplasm: Although some viewpoints are concerned that CD16A cleavage from NK cells may reduce the efficacy of NKCE, evidence from the clinically successful NKCE, AFM13 (CD16A × CD30), has shown that CD16A shedding could reduce the conjugation time between NK cells and target cells, which could in return increase the serial killing capacity of NK cells towards target tumor cells at distant site [202].